I. Kindt

J. Kastelein, B. Hutten, J. Defesche, 2011, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.

CHAPTER 5 No significant improvement of cardiovascular disease risk indicators by a lifestyle intervention in people with Familial Hypercholesterolemia compared to usual care : results of a randomised controlled trial

W. Mechelen, J. Brug, M. Poppel, 2012 .

Systemic Coagulation and Fibrinolysis in Patients with or at Risk for the Adult Respiratory Distress Syndrome

C. Hack, A. Groeneveld, L. Thijs, 1997, Thrombosis and Haemostasis.

J. Brug, W. van Mechelen, M. V. van Poppel, 2012, BMC Research Notes.

Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers.

J. Kastelein, M. Hof, G. Hovingh, 2014, Atherosclerosis.

Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry

J. Knowles, D. Rader, C. Ballantyne, 2023, Journal of the American Heart Association.

Abstract 12169: LDL-C Levels and Treatment Patterns Among Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry

Emily C. O'Brien, J. Knowles, D. Rader, 2015 .

Can Multiple Lifestyle Behaviours Be Improved in People with Familial Hypercholesterolemia? Results of a Parallel Randomised Controlled Trial

J. Brug, W. van Mechelen, M. V. van Poppel, 2012, PloS one.

Abstract: P841 NON-FUNCTIONALITY OF THREE LDL-R AND APOB GENE MUTATIONS THAT WERE ASSUMED TO CAUSE FAMILIAL HYPERCHOLESTEROLEMIA

J. Kastelein, B. Hutten, J. Defesche, 2009 .

Founder mutations in the Netherlands: geographical distribution of the most prevalent mutations in the low-density lipoprotein receptor and apolipoprotein B genes

J. Kastelein, B. Hutten, J. Defesche, 2011, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.

Magnesium pyridoxal–5′–phosphate glutamate, “A vitamin B6 derivative”, does not affect lipoprotein levels in patients with familial hypercholesterolaemia

J. Kastelein, M. Nurmohamed, H. Knipscheer, 1997, European Journal of Clinical Pharmacology.

Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry.

Emily C. O'Brien, J. Knowles, D. Rader, 2014, American heart journal.

Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel.

D. Ledbetter, J. Knowles, D. Rader, 2018, Journal of the American College of Cardiology.

Genetic Testing Preferences and Intentions in U.S. Patients with Clinically Diagnosed Familial Hypercholesterolemia

W. Klein, A. Sturm, L. Erby, 2019, bioRxiv.

Two Years after Molecular Diagnosis of Familial Hypercholesterolemia: Majority on Cholesterol-Lowering Treatment but a Minority Reaches Treatment Goal

J. Kastelein, B. Hutten, M. N. Vissers, 2010, PloS one.

Improved access to life insurance after genetic diagnosis of familial hypercholesterolaemia: cross-sectional postal questionnaire study

M. Netea, J. Meer, S. Alonso, 2012, European Journal of Human Genetics.

Abstract 19888: Improved Longitudinal Low Density Lipoprotein Cholesterol Goal Achievement Among Familial Hypercholesterolemia Patients in the CASCADE FH Patient Registry

Emily C. O'Brien, J. Knowles, D. Rader, 2017 .

Diagnosing Familial Hypercholesterolemia (FH) in the United States: Results from the CASCADE FH Patient Registry*†

Emily C. O'Brien, J. Knowles, D. Rader, 2015 .

INITIAL RESULTS FROM THE CASCADE-FH REGISTRY: CASCADE SCREENING FOR AWARENESS AND DETECTION OF FAMILIAL HYPERCHOLESTEROLEMIA

Emily C. O'Brien, J. Knowles, D. Rader, 2015 .